Compare Vanguard Real Estate Index Fund ETF (VNQ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Real Estate Index Fund ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Real Estate Index Fund ETF trades at $90.73 (market cap $70.80B), while State Street SPDR S&P Biotech ETF trades at $153.7 (market cap $10.11B). The key difference: Vanguard Real Estate Index Fund ETF is far larger — about 7× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Vanguard Real Estate Index Fund ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Real Estate Index Fund ETF for 113 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| VNQ | XBI | |
|---|---|---|
Market Cap | $70.80B | $10.11B |
Volume | 6,073,580 | 12,903,266 |
52-Week High | $100.95 | $169.55 |
52-Week Low | $87.00 | $104.99 |
Typical Hold Time | 113 Days | 38 Days |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VNQ trades at $90.65, up 2.21% today, but faces bearish technical signals with 14 sell indicators versus 5 buys. The ETF has declined nearly 10% in the past month amid rising Treasury yields and Federal Reserve rate hikes, eroding its income appeal. Recent institutional buying by State Street Corp and Envestnet suggests some see value at current levels, while news highlights sector-wide REIT pressures and dividend yield comparisons with Treasury bills.
Outlook remains cautious with technical weakness and interest rate sensitivity posing near-term risks. However, contrarian investors may find opportunity in the sector sell-off if long-term real estate fundamentals hold. Key risks include further rate hikes and economic slowdowns affecting property valuations.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
